Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss – a retrospective study

M. Cioni, A. Nocera, A. Tagliamacco, S. Basso, A. Innocente, I. Fontana, A. Magnasco, A. Trivelli, C. Klersy, A. Gurrado, M. Ramondetta, S. Boghen, L. Catenacci, E. Verrina, G. Garibotto, G.M. Ghiggeri, M. Cardillo, F. Ginevri, P. Comoli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)38-48
Number of pages11
JournalTransplant International
Volume32
Issue number1
DOIs
Publication statusPublished - 2019

Keywords

  • anti-humoral therapy
  • antibody-mediated rejection
  • complement-binding DSA
  • de novo donor-specific anti-HLA antibodies
  • pediatric kidney transplantation
  • complement component C1q
  • complement component C3d
  • HLA antibody
  • immunoglobulin
  • rituximab
  • tacrolimus
  • alloantibody
  • antibody
  • HLA antigen
  • antibody mediated rejection
  • Article
  • child
  • clinical article
  • clinical outcome
  • controlled study
  • disease association
  • drug megadose
  • drug resistance
  • estimated glomerular filtration rate
  • female
  • fluorescence analysis
  • follow up
  • graft failure
  • graft recipient
  • human
  • human cell
  • human tissue
  • kidney function
  • kidney graft rejection
  • kidney transplantation
  • low drug dose
  • male
  • plasmapheresis
  • prediction
  • priority journal
  • prognosis
  • protein binding
  • retrospective study
  • risk assessment
  • treatment failure
  • treatment outcome
  • adolescent
  • biopsy
  • donor
  • graft rejection
  • graft survival
  • immunology
  • kidney
  • multivariate analysis
  • risk
  • Adolescent
  • Antibodies
  • Biopsy
  • Child
  • Female
  • Follow-Up Studies
  • Graft Rejection
  • Graft Survival
  • HLA Antigens
  • Humans
  • Isoantibodies
  • Kidney
  • Kidney Transplantation
  • Male
  • Multivariate Analysis
  • Prognosis
  • Retrospective Studies
  • Risk
  • Rituximab
  • Tissue Donors

Cite this

@article{464b67fff1834c78ae85bf3fb23b8a56,
title = "Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss – a retrospective study",
keywords = "anti-humoral therapy, antibody-mediated rejection, complement-binding DSA, de novo donor-specific anti-HLA antibodies, pediatric kidney transplantation, complement component C1q, complement component C3d, HLA antibody, immunoglobulin, rituximab, tacrolimus, alloantibody, antibody, HLA antigen, antibody mediated rejection, Article, child, clinical article, clinical outcome, controlled study, disease association, drug megadose, drug resistance, estimated glomerular filtration rate, female, fluorescence analysis, follow up, graft failure, graft recipient, human, human cell, human tissue, kidney function, kidney graft rejection, kidney transplantation, low drug dose, male, plasmapheresis, prediction, priority journal, prognosis, protein binding, retrospective study, risk assessment, treatment failure, treatment outcome, adolescent, biopsy, donor, graft rejection, graft survival, immunology, kidney, multivariate analysis, risk, Adolescent, Antibodies, Biopsy, Child, Female, Follow-Up Studies, Graft Rejection, Graft Survival, HLA Antigens, Humans, Isoantibodies, Kidney, Kidney Transplantation, Male, Multivariate Analysis, Prognosis, Retrospective Studies, Risk, Rituximab, Tissue Donors",
author = "M. Cioni and A. Nocera and A. Tagliamacco and S. Basso and A. Innocente and I. Fontana and A. Magnasco and A. Trivelli and C. Klersy and A. Gurrado and M. Ramondetta and S. Boghen and L. Catenacci and E. Verrina and G. Garibotto and G.M. Ghiggeri and M. Cardillo and F. Ginevri and P. Comoli",
note = "Export Date: 28 August 2019 CODEN: TRINE Correspondence Address: Ginevri, F.; Nephrology, Dialysis, Transplantation Unit, IRCCS Istituto Giannina GasliniItaly; email: fabrizioginevri@gaslini.org",
year = "2019",
doi = "10.1111/tri.13325",
language = "English",
volume = "32",
pages = "38--48",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss – a retrospective study

AU - Cioni, M.

AU - Nocera, A.

AU - Tagliamacco, A.

AU - Basso, S.

AU - Innocente, A.

AU - Fontana, I.

AU - Magnasco, A.

AU - Trivelli, A.

AU - Klersy, C.

AU - Gurrado, A.

AU - Ramondetta, M.

AU - Boghen, S.

AU - Catenacci, L.

AU - Verrina, E.

AU - Garibotto, G.

AU - Ghiggeri, G.M.

AU - Cardillo, M.

AU - Ginevri, F.

AU - Comoli, P.

N1 - Export Date: 28 August 2019 CODEN: TRINE Correspondence Address: Ginevri, F.; Nephrology, Dialysis, Transplantation Unit, IRCCS Istituto Giannina GasliniItaly; email: fabrizioginevri@gaslini.org

PY - 2019

Y1 - 2019

KW - anti-humoral therapy

KW - antibody-mediated rejection

KW - complement-binding DSA

KW - de novo donor-specific anti-HLA antibodies

KW - pediatric kidney transplantation

KW - complement component C1q

KW - complement component C3d

KW - HLA antibody

KW - immunoglobulin

KW - rituximab

KW - tacrolimus

KW - alloantibody

KW - antibody

KW - HLA antigen

KW - antibody mediated rejection

KW - Article

KW - child

KW - clinical article

KW - clinical outcome

KW - controlled study

KW - disease association

KW - drug megadose

KW - drug resistance

KW - estimated glomerular filtration rate

KW - female

KW - fluorescence analysis

KW - follow up

KW - graft failure

KW - graft recipient

KW - human

KW - human cell

KW - human tissue

KW - kidney function

KW - kidney graft rejection

KW - kidney transplantation

KW - low drug dose

KW - male

KW - plasmapheresis

KW - prediction

KW - priority journal

KW - prognosis

KW - protein binding

KW - retrospective study

KW - risk assessment

KW - treatment failure

KW - treatment outcome

KW - adolescent

KW - biopsy

KW - donor

KW - graft rejection

KW - graft survival

KW - immunology

KW - kidney

KW - multivariate analysis

KW - risk

KW - Adolescent

KW - Antibodies

KW - Biopsy

KW - Child

KW - Female

KW - Follow-Up Studies

KW - Graft Rejection

KW - Graft Survival

KW - HLA Antigens

KW - Humans

KW - Isoantibodies

KW - Kidney

KW - Kidney Transplantation

KW - Male

KW - Multivariate Analysis

KW - Prognosis

KW - Retrospective Studies

KW - Risk

KW - Rituximab

KW - Tissue Donors

U2 - 10.1111/tri.13325

DO - 10.1111/tri.13325

M3 - Article

VL - 32

SP - 38

EP - 48

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 1

ER -